Tratamiento antirretroviral con nelfinavir en un paciente infectado por el VIH y diabetes mellitus secundaria a indinavir

Pedrol Clotet, Enric; Rodellar Oncins, María Teresa; Soler Sendra, Anna; Martínez Losada, Emilio José.
Med. clín (Ed. impr.) ; 119(10): 398-399, sept. 2002.
Artículo en Es | IBECS (España) | ID: ibc-14830

Documentos relacionados

  1. Hybrid QM/MM Free-Energy Evaluation of Drug-Resistant Mutational Effect on the Binding of an Inhibitor Indinavir to HIV-1 Protease.
  2. Discovery of Novel HIV Protease Inhibitors Using Modern Computational Techniques.
  3. The choice of HIV protease inhibitor: indinavir is currently the best option.
  4. Differences in the Prediction of Area Under the Curve for a Protease Inhibitor Using Trough Versus Peak Concentration: Assessment Using Published Pharmacokinetic Data for Indinavir.
  5. Serum-integrated omics reveal the host response landscape for severe pediatric community-acquired pneumonia.
  6. Artificial intelligence for the optimal management of community-acquired pneumonia.
  7. Microbiology of Severe Community-Acquired Pneumonia and the Role of Rapid Molecular Techniques.
  8. Community-Acquired Pneumonia.
  9. Community-Acquired Pneumonia.
  10. Community-Acquired Pneumonia.